Cybin Inc. Reports Q2 2025 Results and Advances Neuropsychiatry Programs Toward Key 2026 Data Readouts

Cybin Inc. reported second-quarter 2025 results and recent business highlights, noting strong institutional demand for its completed financing, which Interim CEO Eric So said reinforces confidence in the company's science, differentiated therapeutic candidates and ability to execute as it advances toward key 2026 data readouts. The company completed enrollment in its Phase 2 CYB004 study for generalized anxiety disorder, continued progressing CYB003 through the Phase 3 APPROACH and EXTEND trials, and secured additional global regulatory approvals to initiate the EMBRACE(R) Phase 3 study for adjunctive major depressive disorder treatment. These clinical advancements represent significant milestones in the development of novel neuropsychiatry treatments addressing substantial unmet medical needs in mental healthcare.

The company expanded its intellectual property estate to more than 100 granted patents and over 250 pending applications, strengthening its competitive position in the emerging psychedelic medicine space. Cybin's Board formed a committee to conduct a CEO search to guide the next stage of growth and late-stage clinical development, indicating strategic planning for the company's evolution as it approaches critical data readouts. The strong institutional financing demand mentioned by Interim CEO Eric So suggests growing investor confidence in Cybin's approach to developing next-generation mental health treatments, particularly as the company moves closer to pivotal clinical trial results expected in 2026.

Cybin's clinical pipeline includes CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. These programs represent innovative approaches to treating mental health conditions that have historically shown limited response to conventional therapies. Additional information about Cybin's developments is available in the company's newsroom at https://ibn.fm/CYBN.

The progress across multiple late-stage clinical programs simultaneously demonstrates Cybin's operational capabilities and the maturation of the neuropsychiatry treatment field. The company's ability to advance multiple compounds through clinical development stages while expanding its intellectual property portfolio positions it as a leader in the emerging psychedelic medicine sector. The timing of these developments coincides with growing recognition of the limitations of existing mental health treatments and increasing scientific validation of psychedelic-inspired compounds for psychiatric conditions. The upcoming 2026 data readouts will provide critical evidence regarding the efficacy and safety of Cybin's novel therapeutic candidates, potentially validating the company's scientific approach and paving the way for regulatory submissions.